- Top >
- Greetings
Head, Osamu Takikawa, PhD
Lab Radiation Safety,
Natl Center for Geriatr Gerontol
Greetings
We are developing a novel method for prevention,
diagnostication
and therapy for Alzheimers' disease, focusing on metabolic disorder of
protein or amino acid (tryptophan) in the AD brain.
Studying nutrition research on the
anti-aggregating function
of natural product like trehalose to inhibit the toxic protein
accumulation in the brain.
Also the head of Lab Drug Screening,
Metabolic Disorder in Demetia
Some kinds of protein accumulation seems to be occurred as
a
result of metabolic disorder in the brain of AD patient, suggesting
that reduction of the protein accumulation would ameliorate the
dementia. For the precaution or the early treatment of dementia, we are
studying on the absorption, distribution, metabolism and excretion
(ADME) of amyloid beta, tau and amino acid derivatives, to regulate the
intracerebral metabolic levels of the pathogens.
Major Publications (2012~)
| [Literature] |
|---|
| Tanizaki Y, Kobayashi A, Toujima S, Shiro M, Mizoguchi M, Mabuchi Y, Yagi S,Minami S, *Takikawa O, Ino K. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer via inducing immunosuppressive environment. Cancer Sci. 105:966-973, 2014. |
| Lu M, Williamson NR, Boschetti C, Ellis T, *Yoshimi T, Tunnacliffe A. Expression-level dependent perturbation of cell proteostasis and nuclear morphology by aggregation-prone polyglutamine proteins. J Biol Chem, in press. |
| Higashitani K, Kanto T, Kuroda S, Yoshio S, Matsubara T, Kakita N, Oze T, Miyazaki M, Sakakibara M, Hiramatsu N, Mita E, Imai Y, Kasahara A, Okuno A, *Takikawa O, Hayashi N, Takehara T. Association of enhanced activityof indoleamine 2,3-dioxygenase in dendriticcells with the induction of regulatory T cells in chronic hepatitis C infection. J Gastroenterol. 2013 May;48(5):660-70. |
| Wright O, Zhang L, Liu Y, *Yoshimi T, Zheng Y, Tunnacliffe A. Critique of the use of fluorescence-based reporters in Escherichia coli as a screening tool for the identification of peptide inhibitors of Aβ42 aggregation. J Pept Sci. 19:74-83, 2013. |
| *Okada K, Angkawidjaja C, Koga Y, Takano K, Kanaya S. Characteristic features of kynurenine aminotransferase allosterically regulated by (alpha)-ketoglutarate in cooperation with kynurenine. PLoS One. 7:e40307, 2012. |
| Sato N, Saga Y, Mizukami H, Wang D, Takahashi S, Nonaka H, Fujiwara H, Takei Y, Machida S, *Takikawa O, Ozawa K, Suzuki M. Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cellssuppresses tumor growth by promoting natural killer cell accumulation. Oncol Rep. 28:1574-1578, 2012. |
| Tanaka M, Li X, Hikawa H, Suzuki T, Tsutsumi K, Sato M, *Takikawa O,Suzuki H, Yokoyama Y. Synthesis and biological evaluation of novel tryptoline derivatives asindoleamine 2,3-dioxygenase (IDO) inhibitors.Bioorg Med Chem. 21:1159-1165, 2013. |
| Fukuhara K, Ohno A, Ota Y,Senoo Y,Maekawa K, Okuda H, Kurihara M,Okuno A, Niida S, Saito Y, *Takikawa O. NMR-based Metabolomics of Urine in a Mouse Model of Alzheimer's Disease: Identification of Oxidative Stress Biomarkers.J Clin Biochem Nutr. 52:133-138, 2013 |
| Matsuno K, Yamazaki H, Isaka Y, takai K, Unno Y, Ogo N,
Ishikawa Y, Fujii S, *Takikawa O, Asai A. Novel candesartan derivatives
asindoleamine 2,3-dioxygenase inhibitors. Med. Chem. Comm, 3:475-479,
2012. |
| Nakano S, Takai K, Isaka Y, Takahashi S, Unno Y, Ogo N,
Matsuno K, *Takikawa
O, Asai A. Identification of novel kynurenine
production-inhibitingbenzenesulfonamidederivatives in cancer cells.
Biochem Biophys Res Commun, 419:556-561, 2012. |
| Wang D, Saga Y, Mizukami H, Sato N, Nonaka H, Fujiwara H,
Takei Y, Machida S, *Takikawa
O, Ozawa K, Suzuki M. Indoleamine-2,3-dioxygenase, an immunosuppressive
enzyme that inhibits naturalkiller cell function, as a useful target
for ovarian cancer therapy. Int J Oncol, 40:929-934,2012. |
| Wright O, *Yoshimi T, Tunnacliffe
A. Recombinant production of cathelicidin-derived antimicrobial peptides
in Escherichia coli using an inducible autocleaving enzyme tag. N
Biotechnol, 29:352-358, 2012. |
| |
| [Patent pending] |
| PCT/JP2009/006760 |
| |
| |
